Peptide Therapeutics Market Forecast and Growth Insights 2031

Peptide Therapeutics Market Size and Forecast (2021–2031), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Type (Generic and Innovative), Route of Administration (Parenteral, Oral, Mucosal, Pulmonary, and Others), Synthesis Technology [Solid Phase Peptide Synthesis (SPPS), Liquid Phase Peptide Synthesis (LPPS), and Hybrid Technology], Application (Cancer, Cardiovascular Disorder, Metabolic Disorder, Respiratory Disorder, Pain, and Dermatology), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)

  • Report Code : TIPRE00003793
  • Category : Biotechnology
  • Status : Data Released
  • No. of Pages : 150
Buy Now

The peptide therapeutics market size is projected to reach US$ 73.63 billion by 2031 from US$ 29.35 billion in 2023. The market is expected to register a CAGR of 11.5% in 2023–2031. Growing popularity reducing the pace of manufacturing of peptide drugs and adoption of new technologies are likely to remain key peptide therapeutics market trends.

Peptide Therapeutics Market Analysis

As the global burden of chronic diseases increases, the demand for targeted and efficient therapeutic approaches increases. With their precision and specificity, peptide therapeutics are proving to be a compelling solution that meets the therapeutic needs of various chronic diseases. Robust research pipelines promise a future full of novel and breakthrough peptide therapeutics. The shift toward personalized medicine is consistent with the unique properties of peptide therapeutics. As peptides show promise in treating rare diseases, pharmaceutical companies focus on developing therapeutic solutions for niche patient populations. Innovations in synthetic methods lead to more complex and specialized peptides, expanding the therapeutic arsenal available to healthcare professionals. Further, combined efforts in research initiatives between scientists and market players drive innovation in the peptide therapeutics market. Additionally, partnerships and alliances create synergies that advance the development of cutting-edge peptide-based therapies. However, stringent regulations and high drug development costs are expected to restrain market growth.

Peptide Therapeutics Market Overview

The peptide therapeutics market is emerging as a dynamic and promising sector within the pharmaceutical industry, offering a unique approach to treating various diseases and medical conditions. Peptide therapeutics composed of short amino acid sequences have attracted considerable attention due to their specificity, efficacy, and potential applications in various therapeutic areas. This emerging market stands at the intersection of innovation and medical science and is poised to reshape the healthcare landscape. The market includes various peptides, from naturally occurring to synthetic analogs, designed for improved therapeutic results. These peptides are versatile agents targeting specific receptors, enzymes, or cellular mechanisms, making them a valuable tool in precision medicine.

Customize Research To Suit Your Requirement

We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.

Peptide Therapeutics Market: Strategic Insights

Peptide Therapeutics Market

  • CAGR (2023 - 2031)
  • Market Size 2023
    US$ 29.35 Billion
  • Market Size 2031
    US$ 73.63 Billion

Market Dynamics

  • Growing Investments on Peptide Therapeutics
  • Emphasis on Automatic Peptide Synthesis
  • Operational Limitations of Peptides

Key Players

  • Eli Lilly and Company,
  • Amgen Inc.,
  • Teva Pharmaceutical Industries Ltd.,
  • Lonza,
  • Sanofi,
  • Bristol-Myers Squibb Company,
  • GlaxoSmithKline plc.,
  • AstraZeneca,
  • Pfizer Inc.,
  • Novo Nordisk

Regional Overview

  • North America
  • Europe
  • Asia-Pacific
  • South and Central America
  • Middle East and Africa

Market Segmentation

  • Generic
  • Innovative
Route of Administration
  • Parenteral
  • Oral
  • Mucosal
  • Pulmonary
  • Others
Synthesis Technology
  • Solid Phase Peptide Synthesis
  • Cancer
  • Cardiovascular Disorder
  • Metabolic Disorder
  • Respiratory Disorder
  • Pain MAnagement
  • Dermatology
  • Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.

Peptide Therapeutics Market Drivers and Opportunities

Increasing Prevalence of Metabolic Disorders and Infectious Diseases to Favor Market

As per an article in the National Library of Medicine, infectious diseases remain a leading cause of sickness and mortality worldwide, causing more than 52 million deaths per year worldwide. According to the IDF published in December 2021, an estimated 14 million adults in Mexico have diabetes. Peptides such as amide (GLP-1) are effective in treating diabetes. In February 2022, the Nova Scotia provincial government reported that Nova Scotians have registered in pharmacare programs that would begin switching to a biosimilar version of certain biologic medicines, including some insulins and medications, for the treatment of Crohn's disease and rheumatism. The increasing cases of some metabolic disorders, such as organ dysfunction, genetic disorders, and mitochondrial dysfunction, are one of the factors that drive the market growth. The progressive storage of glucocerebrosides in macrophages, primarily in the bone, bone marrow, spleen, and liver are the indications of Gaucher disease (GD) which is an autosomal recessive lysosomal storage disorder. As per the Journal of Pediatric Haematology/Oncology (JPHO), in July 2022, the prevalence of GD cases per 100,000 live births worldwide was 1.5. Therefore, the high prevalence of infectious and metabolic diseases drives the demand for peptide therapeutics for treating these diseases, thereby boosting market growth.

Strong Pipeline and Applications of Peptide Drugs – An Opportunity for Peptide Therapeutics Market Growth

The most common peptide indications are oncology, endocrinology, and metabolic diseases. Other peptide target areas that have received attention include gastroenterology, cardiovascular disease, dermatology, bone diseases, and sexual dysfunction. Due to their high immunogenicity, peptide vaccines also have great potential to become an alternative to classical vaccines as they are completely synthetic and do not cause undesirable side effects. To overcome their limitations, various modifications of peptides have been introduced. Furthermore, the ongoing studies related to the application of peptides are expected to positively impact the pipeline, thereby providing lucrative opportunities for market growth. Some peptide drug pipelines are as follows:



Therapeutic Area

Developmental Stage

3B Pharmaceuticals (Germany)


Oncology-FAP expressing tumours

Phase-I clinical trials

3B 401

Neuroendocrine tumors

Pre-clinical trials

Allysta Pharmaceuticals (US)


Ophthalmology-Dry eye disease

Phase-II clinical trials


Liver diseases and obesity

Phase-I clinical trials

Source: Issar Pharma, Willing Wellness

Peptide Therapeutics Market Report Segmentation Analysis

Key segments that contributed to the derivation of the peptide therapeutics market analysis are component, application, and end user.

  • Based on type, the peptide therapeutics market is divided into generic, and innovative. The innovative segment held the largest share of the market in 2023, whereas the generic segment is anticipated to register the highest CAGR during the forecast period.
  • By route of administration, the market is segmented into parenteral, oral, mucosal, pulmonary, others. The parenteral segment held the largest share of the market in 2023, and oral segment is anticipated to register the highest CAGR during 2023–2031.
  • Based on synthesis technology, the peptide therapeutics market is divided solid phase peptide synthesis (SPPS), liquid phase peptide synthesis (LPPS), hybrid technology. The solid phase peptide synthesis segment held the largest share of the market in 2023. However, the hybrid technology segment is anticipated to register the highest CAGR during the forecast period.
  • In terms of application, the market is segmented into cancer, cardiovascular disorder, metabolic disorder, respiratory disorder, pain, and dermatology. The cancer segment held the largest share of the market in 2023. However, the metabolic disorder segment is estimated to register the highest CAGR during 2023–2031.

Peptide Therapeutics Market Share Analysis by Geography

The geographic scope of the peptide therapeutics market report is mainly divided into five regions: North America, Asia Pacific, Europe, Middle East & Africa, and South America/South & Central America.

North America has dominated the peptide therapeutics market. The growth of the market in North America is attributed to the renowned academic institutions, state-of-the-art laboratories, and collaborations between science and industry contribute to a vibrant R&D ecosystem that promotes the discovery and development of novel peptides with therapeutic potential. In North America, the biotechnology sector in plays an important role in developing peptide therapeutics. The presence of leading biotech companies and a supportive regulatory environment promote translating research findings into clinically viable peptide-based treatments, positioning North America as a leader in the global peptide therapeutics space. The prevalence of chronic diseases in North America highlights the need for advanced therapeutic solutions. With their targeted mechanisms of action, peptide therapeutics are proving to be promising candidates for treating diseases such as diabetes, cardiovascular diseases (CVDs), and various types of cancer. Asia Pacific is anticipated to grow with the highest CAGR in the coming years.

Peptide Therapeutics Market Report Scope

Report Attribute Details
Market size in 2023 US$ 29.35 Billion
Market Size by 2031 US$ 73.63 Billion
Global CAGR (2023 - 2031) 11.5%
Historical Data 2021-2022
Forecast period 2023-2031
Segments Covered By Type
  • Generic
  • Innovative
By Route of Administration
  • Parenteral
  • Oral
  • Mucosal
  • Pulmonary
  • Others
By Synthesis Technology
  • Solid Phase Peptide Synthesis
By Application
  • Cancer
  • Cardiovascular Disorder
  • Metabolic Disorder
  • Respiratory Disorder
  • Pain MAnagement
  • Dermatology
Regions and Countries Covered North America
  • US
  • Canada
  • Mexico
  • UK
  • Germany
  • France
  • Russia
  • Italy
  • Rest of Europe
  • China
  • India
  • Japan
  • Australia
  • Rest of Asia-Pacific
South and Central America
  • Brazil
  • Argentina
  • Rest of South and Central America
Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of Middle East and Africa
Market leaders and key company profiles
  • Eli Lilly and Company,
  • Amgen Inc.,
  • Teva Pharmaceutical Industries Ltd.,
  • Lonza,
  • Sanofi,
  • Bristol-Myers Squibb Company,
  • GlaxoSmithKline plc.,
  • AstraZeneca,
  • Pfizer Inc.,
  • Novo Nordisk
    • Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.

    Peptide Therapeutics Market News and Recent Developments

    The peptide therapeutics market is evaluated by gathering qualitative and quantitative data post primary and secondary research, which includes important corporate publications, association data, and databases. The following is a list of developments in the market for peptide therapeutics:

    • Novo Nordisk announced that the U.S. Food and Drug Administration (FDA) approved an additional indication for Wegovy to reduce the risk of major cardiovascular events such as death, heart attack, or stroke in adults with known heart disease and with either obesity or overweight along with a reduced calorie diet and increased physical activity. (Novo Nordisk A/S, Press Release, 2024)
    • Ono Pharmaceutical Co., Ltd. announced that it entered into a drug discovery collaboration agreement with PeptiDream Inc., to discover and develop novel macrocyclic constrained peptide drugs against multiple targets. Under the terms of the agreement, PeptiDream will identify and optimize macrocyclic constrained peptide drug candidates for multiple targets of interest selected by Ono, by using PeptiDream’s proprietary Peptide Discovery Platform System (PDPS) technology. (Source: ONO PHARMACEUTICAL CO., LTD., News, 2023)
    • Biosynth, a supplier of critical materials to the life science industry, announced the acquisition of Pepceuticals, a UK producer of synthetic peptides with multi-kilogram GMP facilities and fill-finish capabilities designed to support customers from clinical trials to commercial supply. The acquisition enables the support of all phases of the product life cycle from discovery to commercialisation. (Source: Biosynth, News, 2023)
    • IRBM, an innovative contract research organization, announced that it has signed a new agreement with Merck & Co. Inc., to continue their collaboration in the peptide therapeutics area. The collaboration allows to combine IRBM’s first-class scientific expertise in peptide design and synthesis with Merck & Co. Inc.’s exceptional drug development capabilities with a focus on delivering innovative therapies to patients in need. (Source: IRBM S.p.A.; Press Release; 2023)
    • Hokkaido University researchers have developed a novel method to design and develop peptide antibiotics in large numbers, which will prove critical to controlling antibiotic resistance. (Hokkaido University, Press Release, 2023)

    Peptide Therapeutics Market Report Coverage and Deliverables

    The “Peptide Therapeutics Market Size and Forecast (2021–2031)” report provides a detailed analysis of the market covering below areas:

    • Market size and forecast at global, regional, and country levels for all the key market segments covered under the scope
    • Market dynamics such as drivers, restraints, and key opportunities
    • Key future trends
    • Detailed PEST/Porter’s Five Forces and SWOT analysis
    • Global and regional market analysis covering key market trends, major players, regulations, and recent market developments
    • Industry landscape and competition analysis covering market concentration, heat map analysis, prominent players, and recent developments
    • Detailed company profiles
    Report Coverage
    Report Coverage

    Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends

    Segment Covered
    Segment Covered

    Type, and Application

    Regional Scope
    Regional Scope

    North America, Europe, Asia Pacific, Middle East & Africa, South & Central America

    Country Scope
    Country Scope

    Argentina, Australia, Brazil, Canada, China, France, Germany, India, Italy, Japan, Mexico, Saudi Arabia, South Africa, South Korea, Spain, United Arab Emirates, United Kingdom, United States

    The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.

    1. Data Collection and Secondary Research:

    As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.

    Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.

    1. Primary Research:

    The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.

    For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.

    A typical research interview fulfils the following functions:

    • Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
    • Validates and strengthens in-house secondary research findings
    • Develops the analysis team’s expertise and market understanding

    Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:

    • Industry participants: VPs, business development managers, market intelligence managers and national sales managers
    • Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.

    Below is the breakup of our primary respondents by company, designation, and region:

    Research Methodology

    Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.

    1. Data Analysis:

    Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.

    • 3.1 Macro-Economic Factor Analysis:

    We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.

    • 3.2 Country Level Data:

    Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.

    • 3.3 Company Profile:

    The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.

    • 3.4 Developing Base Number:

    Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.

    1. Data Triangulation and Final Review:

    The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.

    We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.

    We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.

    Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

    Trends and growth analysis reports related to Peptide Therapeutics Market